Bisphosphonate therapy

American Journal of the Medical Sciences

Volumn 313, Issue 1, 1997, Pages 17-22

  Licata, Angelo A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiresorption; Bisphosphonates; Bone Density; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; PYROPHOSPHATE; RISEDRONIC ACID; TILUDRONIC ACID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; DISEASE CONTROL; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS;

EID: 0031034009     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199701000-00004     Document Type: Article

References (70)

1. Francis MD, Centner RL. The development of diphosphonates as significant health care products. Journal of Chemical Education. 1978;55:760-6.
2. Francis MD. A brief history of etidronate. In: Summit L; ed, Diphosphorates: The First Decade. A Symposium on Dipliosphonates and the Management of Metabolic Bone Disease, Williamsburg, VA: Virginia Commonwealth University; 1988:7-14.
3. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990;322:1265-71.
4. Watts NB, Harris ST, Genant HK, Wasnick RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis, N Engl J Med. 1990;323:73-9.
5. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose - response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 1989;XV(9):389-96.
6. Fleisch H. Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism, Recent Results Cancer Res. 1989;116:1-27.
7. Lin JH. Bisphosphonates: A review of their pharmacokitic properties. Bone. 1996;18:75-85.
8. Fleisch H, Russell RGG, Francis MD, Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262-4.
9. Boonecamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesing C, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Mineral, 1986;1:27-39.
10. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light Microscopy. J Bone Miner Res. 1990;5:31-40.
11. Sato M, Grasser W, Endo N, Atkins R, Simmons H, Thompson DD, Golub E, et al. Bisphosphonate actionalendronate localization in rat bone and effects on osteoclast ultrastrueture. J Clin Invest. 1991;88:2095-2105.
12. Licata A. From bathtub ring to osteoporosis; A clinical review of the bisphosphonates. Cleve Clin J Med. 1993;60:284-90.
13. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boice BF. A new model for the regulation of bone resorption with particular reference to the effects of bisphosphoantes. J Bone Miner Res. 1996; 11:150-9.
14. Hughes DE, MacDonald BR, Bussell RGG, Gowen M. Inhibition of osteoclast-like cell formation of bisphosphonates in long-term cultures of human bone marrow, J Clin Invest. 1989;83:1930-5.
15. Hughes DE, Wright KB, Sasaki A, Yoneda T, Uy H, et al. Bisphosphonates induce osteoclast apoptosis in vivo and in vitro, but calcitonin does not, J Bone Miner Res. 1994;9(suppl 1):S347.
16. Passeri G, Girasole G, Ulietti V, Giuliani N, Pedrozzoni M, et al. Bisphosphonates inhibit IL-6 production by human osteoblast cells MG-63. J Bone Miner Res. 1994;9:S230.
17. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ, Bisphosphonates act on rat bone resorption through the mediation of osteoblasts, J Clin Invest. 1993;91:2004-11.
18. Vitte C, Fleisch H, Guenther HL. Osteoblasts mediate the bisphosphonate inhibition of bone resorption through synthesis of an osteoclast-inhibiting activity. J Bone Miner Res. 1994;9:S142.
19. Fleisch H. Bisphosphonates: Pharmacology and use in the treatment of tumor-reduced hypercalcemic and metastatic bone disease. Drugs. 1991;42:919-44.
20. King WR, Francis MD, Michael WR. Effect of disodium ethane-1-hydroxy-1 1-diphosphonate on bone formation. Clin Orthop. 1971; July-August:251-70.
21. Adamson BB, Gallacher SJ, Byars J, et al. Mineralization defects with pamidronate therapy for Paget's disease. Lancet. 1998;342:1459-60.
22. Harris ST, Watts NB, Jackson RD, Genant HK, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
23. Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB. Effects of etidronate and phosphate on bone histomorphometry in women with postmenopausal osteoporosis, J Bone Miner Res. 1991;1(suppl 6):S224.
24. Storm T, Stetniohe T, Thamsborg G, Melsen F. Changes in bone histomorphometry after a long-term treatment with intermittent cyclic etidronate for postmenopausal osteorpososis. J Bone Miner Res. 1993;8:199-208.
25. Wimalawansa SJ. Combined therapy with estrogen and etidroaate has an additive effect on mineral density in the hip and vertebrae: Four-year randomized study. Am J Med. 1995;99:36-42.
26. Miller PD, Neil BJ, McIntyre DO, Yanover MJ, Anger MS, Kowalski L. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women, Osteoporos Int. 1991;1:171-76.
27. Silberstein EB, Schnur W. Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years, J Nucl Med. 1992;33:1-5.
28. Rodan GA, Sector JG, Balena R. Preclinical pharmacology of alenclronate. Osteoporos Int. 1993;3:ST-512.
29. Liberman UA, Weiss SR, Broell J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1487-43.
30. Black DM, Cummings SR, Thompson D, et al. Alendronate reduces the risk of vertebral and clinical fractures in women with existing vertebral fractures: results of the fracture intervention trial. Osteoporos Int. 1996;6(Suppl 3):94.
31. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral aleadronate of postmenopausal osteoporosis. J Bone Miner Res. 1994;9:1833-37.
32. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int. 1993;3:S13-16.
33. Valkema R, Vismans FJ, Papapoulos SE, Pauwels EKJ, Bijvoet OLM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with bisphosphonate APD. Bone Mineral, 1989; 5:183-92.
34. Landman JO, Schweitzer DH, Froelich M, Hamdy NAT, Papapoulog SE. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate. J Clin Endocrinol Metab, 1995;80:524-28.
35. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J, Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1994;79:1595-9.
36. Devogelaar JP, Nagant de Deuxchaisnes C. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate): Non-linear increase of lumbar bone mineral density, J Bone Miner Res. 1990;5:8250
37. Fromm GA, Vega E, Plantaleca L, Galich AM, Mautalen CA, Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporos Int. 1991;1:129-33.
38. Lufkin EG, Arqueta R, Whitaker D, Cameron AL, Wong VH, Egans KS, et al. Pamidronate: An unrecognized problem in gastrointestinal toxicity. Osteoporos Int. 1994;4:320-22.
39. Reid IR, Mills DA, Wattie DJ. Ototoxicity associated with intravenous bisphosphonate administration. Calcif Tissue Int. 1995;56:584-85.
40. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SB. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab. 1995;80:3465-8.
41. Thiebaud D, Burckhardt P, Malchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C. Two years effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenupause. Osteoporos Int. 1994;4:76-83.
42. McClung M, Bensen W, Bolognese M, Bonnick S, Ettinger M, Harris S, et al. Risedronate treatment of postmenopausal women with low bone mass: Preliminary data. Osteoporos Int. 1996;6;S257.
43. Johnston Jr CC, Bekker PJ, Ouweland FVD, Horowitz ZD, Rupich R, Digennaro J, et al. Risedronate prevention of bone loss in early postmenopausal women (abstract), Calcif Tiss Int. 229:479.
44. Mortensen L, Bekker P, Digennaro J, Axelrod D, Charles P, Johnston CC. Prevention of early postmenopausal bone loss by risedronate: A one-year follow-up data (abstract). Bone. 1995;17:607.
45. Langdahl B, Eriksen EF, Mortensen L, Charles CC, Bekker P, Axelrod D. Histomorphometry from a three-year risedronate loss prevention study (abstract). Bone. 1995;17:607.
46. Bekker P, Licata A, Harris S, Genant H, et al. Residronate dose response in prevention of early postmenopausal bone loss. American Journal of Bone Mineral Research. 1996;11(suppl 1):S346.
47. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, et al. Cyclical clondronate is effective in preventing postmenopausal bone loss: A comparative study with transoutaneous hormone replacement therapy. J Bone Miner Res, 1995; 10: 697-703.
48. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone, 1993; 14:137-41.
49. Filipponi P, Gristallini S, Rizzello E, Policani G, Fedeli L, et al. Five-year cyclical clodronate increases bone mineral density in postmenopausal osteoporosis. Effect on new vertebral fractures (abstract). Calcif Tiss Int. 1095;56:479.
50. Chesnut CH, Reginster J-Y; eds. Proceedings of an official satellite symposium held at the XIITH international conference on calcium regulating hormones. Bone, 17;5S:471-519.
51. Reginster J-Y, Deroisy R, Dennis D, Collette J, Lecart MP, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;2:1469-71.
52. Murakami H, Nakamwra T, Tsurukami H, Abe M, Barbier A, Suzuki K. Effects of tiludronate on bone mass, structure and turnover at the epihyseal, primary, and secondary spongiosa in the proximal tibia of ruined rats after sciatic neurectomy. J Bone Miner Res. 1994;9:1355-64.
53. Geusens P, Nijs J, Vanderperre G, Vanaudekercke R, Lowet G, Goovaerts S, et al. Longitudinal effect of tiludronate on bone mineral density, resident frequency on strength in monkeys. J Bone Miner Res. 1992;7:599-609.
54. Struys A, Snelder AA, Mulder H, Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med. 1995;99:235-42.
55. Worth H, Stammen D, Keck E, Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D and a diphoaphonate. Am J Resp Crit Care Med. 1994;150:394-97.
56. Diamond T, McGuij NL, Barbagallo S, Bryant C, Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med. 1995; 98:459-63.
57. Molder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss, Br J Rheumatol. 1994;33:348-50.
58. Blanch J, Pacifici R, Chines A. Pregnancy-associated osteoporosis. Report of two cases of long-term bone density follow-up. Br J Rheumatol. 1994;33:269-72.
59. Valero MA, Loinez C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tiss Int. 1995;57:15-19.
60. Bishop NJ, Williams DM, Compton JC, Stirling DM, Prentice A. Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor, Br J Haematol. 1995;89:927-28.
61. Licata AA. Treatment of osteoporosis in a patient with homo- cysteinemia (uria) using etidronate disodium and pyridoxine. J Bone Miner Res. 1995;10(suppl 1):S509.
62. Kung AWC, Ng F, Cyclical etidronate prevents bone loss induced by thyroxine treatment in rats (abstract). Endocrine Soc Meeting. 1993:307.
63. Reid IR, Schooler BA, Stewart AW, Prevention of glucocurticoid-induced osteoporosis, J Bone Miner Res. 1990; 5:619-23.
64. Ostlere L, Warner T, Maunier PJ, Hulme P, Hesp R, et al. Treatment of type I Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). QJM. 1991;79:503-15.
65. Chappard D, Minaire P, Privat C, Berard E, Mendoza-Sarmiento J, Taurnebis CH, et al. Effects of tiludronate on bone loss in paraplegic patients, J Bone Miner Res. 10:112-18.
66. Clemens MR, Fessle K, Heim ME, Multiple myeloma: Effect of daily dichloroethylene bisphosphonate on skeletal complications. Ann Hematol. 1993;66:141-46.
67. Jantunen E, Lahtinen R, Laakao M, Use of clodronate in multiple myeloma, Leuk Lymphoma. 1995;19:207-11.
68. Elomaa I, Bloinqvist C, Porkka L, Holmstrom T. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone. J Int Med. 1989;225:59-61.
69. Rizzoli R, Stoermann C, Ammann P, Bonjour JP. Hypercalcemia and hyperosteolysis in vitamin D intoxication: Effects of clodronate therapy. Bone, 1994;15:193-8.
70. Cundy T, Beneton MN, Darby AJ, et al. Osteopenia in systemic mastocytosis: Natural history and responses to treatment with inhibitors of bone resorption, Bone. 1987; 8:149-55.